Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by CStone Pharmaceuticals

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LCB71

            Therapeutic Area: Oncology Product Name: LCB71

            Highest Development Status: Preclinical Product Type: Large molecule

            Recipient: LegoChem Biosciences

            Deal Size: $353.5 million Upfront Cash: $10.0 million

            Deal Type: Licensing Agreement October 29, 2020

            Details:

            CStone obtains the exclusive global right to lead development and commercialization of LCB71 outside the Republic of Korea. LCB71 is a pre-clinical ADC entering into Investigational New Drug (IND) enabling studies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: EQRx

            Deal Size: $1,300.0 million Upfront Cash: $150.0 million

            Deal Type: Licensing Agreement October 27, 2020

            Details:

            Agreement provides a pathway to bring CStone's sugemalimab and CS1003 to global patient communities by partnering with a company with an innovative business model and unique ability to commercialize these two assets competitively against established treatments.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $480.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 30, 2020

            Details:

            This collaboration provides financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab,Oxaliplatin,Capecitabine

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 24, 2020

            Details:

            CS1001-201 study demonstrated an objective response rate of 44.7% , a complete response rate of 31.6%, mOS of 19.7 months and an one-year overall survival rate of 55.5% in patients with relapsed or refractory extranodal natural killer /T cell lymphoma treated with sugemalimab.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            FDA has completed their review of the Investigational New Drug application for anti-PD-L1 monoclonal antibody sugemalimab (CS1001) monotherapy in the relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) with study may proceed (SMP) letter received.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            CS1001-302 is the first randomized double-blind phase III clinical trial of anti-PD-L1 monoclonal antibody combined with chemotherapy as a first-line treatment in patients with stage IV squamous and non-squamous non-small cell lung cancer (NSCLC) histological subtypes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pralsetinib

            Therapeutic Area: Oncology Product Name: BLU-667

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            Pralsetinib was well-tolerated, and showed deep and durable clinical activity in Chinese patients with RET-fusion NSCLC who were enrolled in the global, registrational phase I/II ARROW trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pralsetinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Burning Rock Dx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: collaboration June 29, 2020

            Details:

            The companies will co-develop and commercialize companion diagnostics (CDx) for pralsetinib, an investigational treatment developed by CStone’s partner Blueprint Medicines, in China for the detection of RET alterations in cancer patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avapritinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 22, 2020

            Details:

            Avapritinib has demonstrated outstanding antitumor activity and a well-tolerated safety profile in advanced PDGFRA exon 18 mutant GIST and fourth-line GIST.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Avapritinib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 27, 2020

            Details:

            Data demonstrated an ORR of 84% with most adverse events reported as Grade 1 or 2 for avapritinib in patients with advanced GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.

            PharmaCompass